Clinical Research and Regulatory Affairs Case Studies
Healthcare5 Case StudiesUpdated Sep 2026
Clinical research sites and sponsor teams work where two sets of obligations meet: the care a participant needs, and the protocol and regulatory requirements that govern how a study is run and documented. The five cases come from that setting. They cover a symptom change that was not escalated, a handover that hid overdue results, a shortage of screening capacity, an uneven pattern of protocol deviations, and a consent question raised by new safety information. Each one asks what the participant needs, what the evidence shows, who must coordinate, and which protocols apply.
Case Study 1
Changing symptoms and a delayed escalation in a trial
Corwen Ridge Clinical Unit, a hospital-affiliated research site running nine active studies across oncology and cardiology.
The situation
A participant enrolled in an oncology study returned for a scheduled visit and reported a cough that had started about two weeks earlier, along with tiredness that was worse in the afternoons. The study's safety section listed several events that had to be reported, and Marisol, the coordinator, noticed that one of them overlapped with the new symptoms. The visit flowsheet recorded the complaint, but the free-text field was brief and the physician did not review it until the afternoon. The first reviewer, Tomas, a research nurse, judged the change to be probably minor and placed a routine follow-up three weeks out.
The challenge
The team had to decide whether the change met the threshold for expedited review under the protocol, and whether it warranted an earlier visit. The evidence was thin: one new symptom, no abnormal result yet, and a participant who felt she was managing. The sponsor's safety contact had not been told, and the reporting timelines in the protocol were counted from the point the site considered an event reportable. Nobody on the team was sure who owned that judgment on a day when the principal investigator was away.
Analysis
Teams grounded in Clinical Research and Regulatory Affairs usually start by separating what the participant needs now from what the file can prove later. Here the need was a prompt clinical review, because a new cough alongside fatigue can change quickly and the participant had no other contact point until the next visit. The evidence was incomplete rather than absent, a common trap in this kind of case. A flowsheet entry that reads as routine can hide an event that the protocol requires the team to assess against a defined list. The protocol, not the nurse's impression, set the test for escalation, and the team had to apply it that day.
Coordination failed at two points: the flowsheet did not route to the physician in time, and the scheduling template had no way to hold an unplanned assessment. A better arrangement would give the coordinator a same-day channel to the investigator for any new symptom that matches a listed safety event, with a named backup when the investigator is away. Tomas acted within the existing plan, but the plan itself lacked a trigger. Documenting the reasoning, including a decision not to escalate, protects everyone involved.
Actions taken
- Add a same-day escalation path from the coordinator to the investigator for any new symptom that matches a listed safety event, with a named backup for leave days.
- Revise the visit flowsheet so that any new complaint requires a coded yes or no answer against the listed events before the visit can close.
- Reserve two unplanned assessment slots each week in the scheduling template so that a symptom review never waits for the next routine visit.
- Hold a monthly audit of symptom complaints that were not escalated, comparing each against the protocol definitions and recording the reasoning on file.
Results
The participant was seen within two days after the coordinator escalated the complaint, and the investigator judged the findings did not require a change to the study plan, though the event was recorded and reported as the protocol required. The flowsheet change caught two similar complaints later, and both were routed the same day. The audit found one earlier complaint closed without escalation, which the team documented as a process gap rather than an individual error. The lesson was that the protocol already held the answer, and the workflow had not been built to reach it.
Questions for discussion
- Which parts of the flowsheet entry should have been coded so that a reviewer could see the link to a listed event without reading the free text?
- How should a site decide who holds the escalation judgment when the investigator is unavailable, and where should that decision be written down?
- What evidence would the team need before concluding that a symptom change was unrelated to the investigational product, and who should review it?
Case Study 2
A coordinator handover gap during staff leave
Thornmere Clinical Research Group, a sponsor-investigator network with four enrolling locations and a shared central laboratory liaison.
The situation
Four weeks into a long-term follow-up study, the coordinator who ran the lead site, Ines, went on unplanned leave. Her handover to a covering coordinator, Gareth, was a forty-minute call and a shared spreadsheet with the open visits. The spreadsheet listed scheduled visits and their windows, but not the laboratory results that had come back outside the expected range and were waiting for physician review. Those results sat in the lab portal under a different participant identifier format. Two participants had results that needed a same-week decision, and neither appeared on the sheet. Gareth found the gap only when a participant called to ask why nobody had contacted her.
The challenge
The team needed to establish what had been missed, whether either participant had come to harm, and how to contact both before the end of the day. Neither result was an emergency on its face, but the protocol set a review window that had already closed for one of them. The covering coordinator had no access to the physician's inbox and had to route questions through a manager who was in a different time zone. Records showed the handover was signed as complete, which hid the gap.
Analysis
The participants' needs were specific and time-bound. One had a result that might change the next step in her follow-up, and the other had a result that needed a repeat decision within the week. The team's evidence was the lab report itself, which was unambiguous, and the protocol's list of result categories that required physician action. What was missing was the link between the report and the participant's file. A handover document is only as good as the list it carries, and this one was built from the visit calendar rather than from open clinical tasks. The safeguard belongs in the source systems.
Coordination depended on one call and one spreadsheet, which put the whole transfer on the outgoing coordinator's memory. A structured handover would have named each open task, the owner, the due date, and the escalation route if the owner was unavailable. The protocol required a physician review for out-of-range results, but it did not say how a covering staff member should reach the investigator when the usual reviewer was away. Those are the places where safety quietly leaks. Good practice is to treat the handover as a controlled document that the receiving coordinator signs back item by item against the source record.
Actions taken
- Move every open clinical task, including results awaiting review, into one shared task list that is generated from the source systems rather than typed by hand.
- Require a structured handover form that names each open item, its owner, its due point, and a named covering physician for any unreviewed result.
- Run a reconciliation at the start of each covering period, in which the receiving coordinator checks the task list against the lab portal for the previous two weeks.
- Add an identifier cross-reference so that participant numbers in the lab portal and the study database match, and flag any mismatch at enrollment.
Results
The site rebuilt the handover form and reconciled the open list in the first week of the new process. Both participants were contacted the same day, and the physician reviewed each result before the end of the window it had missed, documenting the late review as a deviation. The reconciliation found three other open items that had been closed in the spreadsheet but still required action. The identifier mismatch affected about one record in twelve from the lab feed. No participant was harmed, but the event was logged as a near miss and reported through the sponsor's route.
Questions for discussion
- Which fields in a handover form would have made the two overdue results visible to a covering coordinator who had never worked on the study?
- How much verification should a receiving coordinator perform against source records, and what can safely be left to the outgoing coordinator's summary?
- Who should own the decision to reschedule a result review that falls outside the protocol window when the usual reviewer is unavailable?
Case Study 3
Allocating limited screening capacity across three studies
Dunmore Ridge Trial Center, an outpatient research unit with one screening clinic, two imaging suites, and a pool of five coordinators.
The situation
Three studies opened enrollment together, and the screening clinic received referrals faster than it could schedule them. The clinic had two imaging suites that also served the hospital's clinical patients, so research slots were limited to a few mornings each week. Screening visits for one study required a baseline imaging session within a fixed window, which made scheduling less flexible than in the other two. Each study had a monthly enrollment target that the sponsors tracked closely. The unit's coordinators reported that referrals had doubled within a single month, while the number of trained staff available for screening had not changed.
The challenge
The unit could not screen everyone, and the question was which referrals to protect. Screening too many people quickly would mean rushed eligibility checks and incomplete imaging, which undermines the data each study needs. Screening too few would miss enrollment targets and leave referred people waiting with no information. The sponsors wanted assurance that no eligibility shortcut would be taken, and the imaging team wanted a schedule it could keep without overtime.
Analysis
The people waiting for screening had needs that did not change with the calendar. Some had symptoms that made a timely assessment important. Triage for research screening is not the same as clinical triage, but the same principle applies: urgency should follow the person's situation, not the order of the referral. The evidence the team relied on was the eligibility criteria in each protocol and the imaging window that each study specified. Where the window was narrow, a delay of a few days could mean a repeat assessment and a lost slot. The team agreed to tag each referral with its window and any concern the referring clinician had noted.
The unit considered three options. Strict triage by referral date was simple and fair on paper, but it ignored which studies had short windows and would have lost the narrow-window participants. Block scheduling of imaging slots by study protected the windows but left unused time whenever one study had fewer referrals. A shared pool, with a weekly allocation meeting where coordinators and the imaging lead moved slots against the protocol windows, was slower to run and relied on people speaking up. The team chose a mix: a shared pool for routine slots, reserved blocks for the narrowest windows, and a rule that no eligibility check would be shortened.
- 1Strict referral orderFair on paper but ignores short imaging windows and narrow eligibility.
- 2Block scheduling by studyProtects windows but leaves slots empty when referrals are uneven.
- 3Shared pool with weekly reviewFills gaps and moves slots, but depends on coordinators raising conflicts.
- 4Reserved blocks for narrow windowsKeeps time-critical screening visits from losing their window.
- 5Documented no-shortcut ruleEligibility checks and imaging reads are never cut to fit the schedule.
Actions taken
- Tag every referral with its protocol window, its study, and any clinical concern the referring clinician has recorded, before it enters the queue.
- Hold back two imaging blocks each week for the narrowest-window study, released to other studies only after the block has passed its booking deadline.
- Run a fifteen-minute allocation meeting twice a week with the imaging lead and one coordinator from each study to move unused slots.
- Write down that eligibility checks and imaging reads are never shortened to fit the schedule, and make that rule visible to sponsors at the start of enrollment.
Results
Referral waits fell across all three studies over the next two months, though the narrowest-window study still had the longest wait. Two participants who would previously have lost their window were screened in time, and one was enrolled. The unused slots that the old block method left empty were filled on most days. Coordinators reported fewer last-minute reschedules, and the imaging lead said the weekly meeting was the first time the three studies had been compared on a single page. Enrollment targets were met for two of the three studies. The third fell short of its target.
Questions for discussion
- What information should a referral carry so that a scheduler can judge the urgency of a screening visit without calling the referring clinic?
- When two studies compete for the same imaging slot, who should have the authority to decide, and what record should that decision leave behind?
- How should a unit explain a missed enrollment target to a sponsor when the cause was a capacity decision that protected screening quality?
Case Study 4
Inconsistent protocol deviation rates across three sites
Halloran Pike Studies Network, a regional group of three sites that pools anonymized monitoring indicators each cycle.
The situation
The network's quality committee reviewed its monitoring indicators and found that one site reported protocol deviations at nearly three times the rate of the other two. The indicators were anonymized at the site level, so the committee saw counts and categories but not individual participants. The deviations were mostly out-of-window visits and missed sample collection timepoints. The two lower-rate sites had also changed their monitoring schedule in the same period, which made the comparison harder to read. The committee chair, Beatriz, asked whether the difference reflected real practice or how the sites recorded events.
The challenge
The committee needed to know whether the higher rate reflected care that was less consistent, reporting that was more thorough, or a difference in the participants enrolled. Each explanation pointed to a different response. Acting on the wrong one could mean retraining staff who were already following the protocol, or missing a real scheduling problem at the busiest site. Time was also limited: the next data cycle was close, and the sponsor wanted a response in the monitoring report.
Analysis
The participants at the high-rate site were not less well cared for on the evidence the committee had. Their clinical outcomes, which were reviewed through the safety reports, did not differ from the other sites. That matters because a deviation is a departure from the protocol, not automatically a harm, and the committee needed to keep those two ideas apart in its language. The evidence that mattered was the timing data for each visit, compared against the protocol windows, and whether the late visits clustered on particular days or particular staff. A pattern of late visits on one weekday points to a process.
Coordination across three sites rested on a shared data dictionary, but the dictionary defined a deviation at the level of the event, not the timing rule. One site logged a visit as deviating when it was more than a day outside the window, while the others logged it only outside the full window. That single difference could account for much of the gap. The protocol set the windows, but the monitoring manual governed how deviations were logged, and the two had drifted apart. Good practice is to confirm that every site applies one definition before comparing rates, and to name the owner of that definition.
- Start of reviewCommittee compares indicators and notices the high-rate site.
- First two weeksShared definition agreed and the deviation log rebuilt by weekday.
- Week five onwardFour-week reminder change runs at the high-rate site alone.
- End of the cycleLate-visit rate compared with the prior period and reported to sponsor.
- Next monthly reviewDefinition change logged in the manual and cycle repeated if needed.
Actions taken
- Agree one written definition of an out-of-window visit and a missed timepoint, and apply it at all three sites before any rates are compared again.
- Split the deviation log by weekday, staff role, and time to next visit, so that clusters show whether the cause is scheduling, workload, or recording.
- Run a four-week change at the high-rate site that adds a reminder ten days before each visit window opens, and compare its late-visit rate with the prior period.
- Hold a monthly review in which the three site leads and the data manager read the indicator together, and record any change to the definition in the manual.
Results
The shared definition alone reduced the gap between the sites by a little under half. The remaining difference clustered on Mondays at the high-rate site, where a shared staffing gap meant the visit coordinator was also covering the monitoring calls. The reminder change reduced late visits by roughly a third over its four weeks, and the site lead asked to keep it. The committee reported the revised rates with a note on the definition change, so the sponsor could read the trend correctly. The cause was scheduling more than practice, and the fix was a staffing decision.
Questions for discussion
- Which of the three explanations for the rate gap could the existing data rule out, and which would need a different kind of record to test?
- How should a network balance a shared definition against local reporting habits that sites have built up over time?
- What would a monitoring report need to show for a sponsor to read a definition change as a correction rather than a decline in performance?
Case Study 5
Consent questions raised by new safety information
Ardent Hollow Research Partners, a contract research site with a dedicated ethics liaison and an independent participant advocate.
The situation
Dolores had been enrolled in a long-running study for several months when the sponsor issued updated safety information describing a risk that had not been in the original consent form. She was a retired teacher, and her daughter attended most visits and often answered questions on her behalf. The coordinator, Amir, had to arrange a discussion of the new information, but Dolores had asked that her daughter not receive details of her results without her agreement. The site also had to decide whether the updated information required the participant to re-confirm consent, and whether the study team could share that process with the daughter.
The challenge
The team had to balance three duties that pointed in different directions. The participant's right to decide what she was told and who received it was clear. The protocol required that any new risk information be provided to participants, and the sponsor expected documented confirmation. The daughter was a caring and involved presence, and her questions were reasonable, but she was not the decision maker. Nobody on the team could tell from the record whether Dolores had asked for her daughter to be present or only tolerated it.
Analysis
Dolores needed accurate information about a risk that could bear on her decision to continue, and she needed it in a form she could absorb and question. The evidence the team had was the sponsor's updated safety communication, which described the risk in general terms and did not say how it applied to any particular participant. That gap is ordinary and it matters. The site could not translate the update into a personal estimate, so the honest course was to present what was known, what was not, and when more would be learned. Her own record, including her visit notes and the symptoms she had reported, was also evidence.
The consent process belongs to the investigator and the site. The confidentiality of the participant's information is governed by the protocol, and any change to consent is the sponsor's and the ethics committee's concern. Before the discussion, the team should agree with Dolores how she wants information shared, and record that agreement. If she wants her daughter present, the conversation can include her, with the participant leading. If she does not, the team says what it will share with her daughter and what it will not. Escalation goes to the principal investigator and the ethics liaison before any new consent form is used.
Actions taken
- Hold a private conversation with Dolores before the group discussion to ask how she wants information shared, and record her answer in her own words.
- Give the participant a written summary of the updated information in plain language, and offer a second conversation within the week if she wants one.
- Refer the consent question to the principal investigator and the ethics liaison in writing, and do not use a revised consent form until they have approved the approach.
- Record the confidentiality agreement in the participant's file, including who may receive results, and check it at each visit so that a change in circumstances is caught early.
Results
Dolores took up the offer of a second conversation, held with the investigator and, at her request, her daughter present. Her decision to continue was recorded after the revised information was explained, and the ethics liaison confirmed that the approach met the committee's conditions. Her daughter was given only the information Dolores agreed to share. The site found that the early private conversation changed the tone of the later group discussion, because the questions had already been asked. The sponsor received the documentation in time for its monitoring review.
Questions for discussion
- What should a site record when a participant asks that a family member be kept from certain information, and how should that request be revisited if circumstances change?
- How much of an updated risk description should a coordinator be able to explain in plain language before the principal investigator becomes involved?
- When a participant's understanding seems uncertain but she still wants to continue, what evidence should the team gather before deciding whether to pause enrollment steps?
Learning Resources
Healthcare CASE STUDIES
China, India, United States, Indonesia, Pakistan, Nigeria, Brazil, Bangladesh, Russia, Japan, Mexico, Philippines, Vietnam, Egypt, Turkey, Germany, United Kingdom, France, Italy, Canada, South Korea, Australia, Spain.